The two Pt(IV) complexes (OC-6–33)-(cyclohexane-1R,2R-diamine)dichloridodiheptanoatoplatinum(IV) (1) and (OC-6–33)-(cyclohexane-1R,2R-diamine)dichloridodioctanoatoplatinum(IV) (2) were formulated with Intralipid® (IL) as a proof-of-concept to evaluate the delivery of lipophilic metal compounds to cancer cells. Negatively charged nanoemulsions ranging from 287 to 312 nm were obtained. The IL formulations show an increase in cancer cell accumulation (A2780 ovarian cancer cells) by a factor 6–7 with respect to the free complexes. In spite of the expected antiproliferative properties, in the cytotoxicity experiments free complexes showed values of the half-maximal inhibitory concentration (IC50) from 2 to 6 times lower with respect to the IL formulations. However, the presence of IL was not totally detrimental of the potency, that is still in the nanomolar range, and, hence, a possible use in vivo, should not be excluded a priori.

Formulations of highly antiproliferative hydrophobic Pt(IV) complexes into lipidic nanoemulsions as delivery vehicles

Ferraris C.;Battaglia L. S.;
2022

Abstract

The two Pt(IV) complexes (OC-6–33)-(cyclohexane-1R,2R-diamine)dichloridodiheptanoatoplatinum(IV) (1) and (OC-6–33)-(cyclohexane-1R,2R-diamine)dichloridodioctanoatoplatinum(IV) (2) were formulated with Intralipid® (IL) as a proof-of-concept to evaluate the delivery of lipophilic metal compounds to cancer cells. Negatively charged nanoemulsions ranging from 287 to 312 nm were obtained. The IL formulations show an increase in cancer cell accumulation (A2780 ovarian cancer cells) by a factor 6–7 with respect to the free complexes. In spite of the expected antiproliferative properties, in the cytotoxicity experiments free complexes showed values of the half-maximal inhibitory concentration (IC50) from 2 to 6 times lower with respect to the IL formulations. However, the presence of IL was not totally detrimental of the potency, that is still in the nanomolar range, and, hence, a possible use in vivo, should not be excluded a priori.
535
120859
120864
Cell uptake; Cytotoxicity; Drug targeting and delivery; Nanomedicines; Pt(IV) complexes
Gabano E.; Ferraris C.; Osella D.; Battaglia L.S.; Ravera M.
File in questo prodotto:
File Dimensione Formato  
articolo intralipid platino.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 470.28 kB
Formato Adobe PDF
470.28 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
articolo intralipid platino.pdf

Accesso aperto con embargo fino al 25/05/2024

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 1.8 MB
Formato Adobe PDF
1.8 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1862521
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact